Monopar Wins FDA Rare Pediatric Disease Designation
I'm LongbridgeAI, I can summarize articles.Monopar Therapeutics announced that the FDA granted Rare Pediatric Disease designation to its late-stage Wilson disease candidate ALXN1840. This designation recognizes the burden of Wilson disease and positions ALXN1840 as a potential new treatment option. The company highlighted positive Phase 3 trial data showing sustained copper mobilization and favorable safety. While analyst ratings vary, with some suggesting a Buy, AI analysis notes neutral sentiment due to weak financials despite strong clinical progress.
Monopar Therapeutics Inc ( (MNPR) ) has provided an update.
On June 30, 2026, Monopar Therapeutics announced that the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to its late-stage Wilson disease candidate ALXN1840 (tiomolibdate choline). The designation, aimed at serious conditions primarily affecting children, recognizes the burden of Wilson disease and positions ALXN1840 as a potentially important new option for this rare genetic copper disorder.
Existing clinical data show ALXN1840 met the primary endpoint in a Phase 3 pivotal trial, delivering rapid, sustained copper mobilization beyond standard of care over 48 weeks and demonstrating durable clinical benefit with a favorable safety profile across 645 patient-years in 266 patients. The regulatory milestone strengthens Monopar’s profile in rare disease drug development and could enhance the value of its Wilson disease franchise as it advances toward possible U.S. approval.
The most recent analyst rating on (MNPR) stock is a Buy
with a $117.00 price target.
To see the full list of analyst forecasts on Monopar Therapeutics Inc stock,
see the MNPR Stock Forecast page.
Spark’s Take on MNPR Stock
According to Spark, TipRanks’ AI Analyst, MNPR is a Neutral.
The score is held back primarily by weak financial performance (no revenue, widening losses, and rising cash burn) and loss-driven valuation. Offsetting these are strong technical momentum and a meaningful set of positive clinical-data corporate events that improve the near-term narrative, though funding and execution risk remain central.
To see Spark’s full report on MNPR stock,
click here.
More about Monopar Therapeutics Inc
Monopar Therapeutics Inc., based in Wilmette, Illinois, is a clinical-stage biopharmaceutical company focused on treatments for patients with unmet medical needs. Its pipeline centers on ALXN1840 for Wilson disease and a suite of radiopharmaceutical programs, including MNPR-101-Zr for imaging advanced cancers and MNPR-101-Lu and MNPR-101-Ac for treating advanced malignancies.
The company develops novel agents such as ALXN1840, a once-daily oral albumin tripartite complex activator designed to mobilize and sequester excess copper in Wilson disease patients. Monopar’s oncology-focused radiopharmaceuticals target advanced cancers, aiming to improve diagnostic imaging and therapeutic outcomes in highly competitive specialty markets.
Average Trading Volume: 171,687
Technical Sentiment Signal: Buy
Current Market Cap: $587.4M